49 related articles for article (PubMed ID: 38568917)
21. Favorable function of Ectonucleoside triphosphate diphosphohydrolase 1 high expression in thyroid carcinoma.
Luo JH; Zhu YH; Xiang C
Hereditas; 2021 Aug; 158(1):33. PubMed ID: 34465393
[TBL] [Abstract][Full Text] [Related]
22. Using Tumor-Infiltrating Immune Cells and a ceRNA Network Model to Construct a Prognostic Analysis Model of Thyroid Carcinoma.
Zhang F; Yu X; Lin Z; Wang X; Gao T; Teng D; Teng W
Front Oncol; 2021; 11():658165. PubMed ID: 34141614
[TBL] [Abstract][Full Text] [Related]
23. The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy.
Kandel S; Adhikary P; Li G; Cheng K
Cancer Lett; 2021 Jul; 510():67-78. PubMed ID: 33895262
[TBL] [Abstract][Full Text] [Related]
24. Thyroid cancer incidence trends by histology in 25 countries: a population-based study.
Miranda-Filho A; Lortet-Tieulent J; Bray F; Cao B; Franceschi S; Vaccarella S; Dal Maso L
Lancet Diabetes Endocrinol; 2021 Apr; 9(4):225-234. PubMed ID: 33662333
[TBL] [Abstract][Full Text] [Related]
25. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ
J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173
[TBL] [Abstract][Full Text] [Related]
26. New Therapies for Advanced Thyroid Cancer.
Laha D; Nilubol N; Boufraqech M
Front Endocrinol (Lausanne); 2020; 11():82. PubMed ID: 32528402
[TBL] [Abstract][Full Text] [Related]
27. T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer.
Jia K; He Y; Dziadziuszko R; Zhao S; Zhang X; Deng J; Wang H; Hirsch FR; Zhou C; Yu H; Zhang L
Transl Lung Cancer Res; 2019 Dec; 8(6):895-906. PubMed ID: 32010568
[TBL] [Abstract][Full Text] [Related]
28. Significance of TIM-3 Expression in Resected Esophageal Squamous Cell Carcinoma.
Zhao Y; Chen D; Wang W; Zhao T; Wen J; Zhang F; Duan S; Chen C; Sang Y; Zhang Y; Chen Y
Ann Thorac Surg; 2020 May; 109(5):1551-1557. PubMed ID: 31987829
[TBL] [Abstract][Full Text] [Related]
29. Current Knowledge of Germline Genetic Risk Factors for the Development of Non-Medullary Thyroid Cancer.
Hińcza K; Kowalik A; Kowalska A
Genes (Basel); 2019 Jun; 10(7):. PubMed ID: 31247975
[TBL] [Abstract][Full Text] [Related]
30. Knockdown of KDM1A suppresses tumour migration and invasion by epigenetically regulating the TIMP1/MMP9 pathway in papillary thyroid cancer.
Zhang W; Sun W; Qin Y; Wu C; He L; Zhang T; Shao L; Zhang H; Zhang P
J Cell Mol Med; 2019 Aug; 23(8):4933-4944. PubMed ID: 31211500
[TBL] [Abstract][Full Text] [Related]
31. T-Cell Lymphopenia in Patients with Advanced Thyroid Carcinoma Is Associated with Poor Prognosis.
Rabold K; Gielen PR; Kers-Rebel ED; Netea MG; Smit JWA; Adema GJ; Netea-Maier RT
Oncologist; 2019 Mar; 24(3):e106-e110. PubMed ID: 30606882
[TBL] [Abstract][Full Text] [Related]
32. Identification of Key Pathways and Genes in Anaplastic Thyroid Carcinoma via Integrated Bioinformatics Analysis.
Hu S; Liao Y; Chen L
Med Sci Monit; 2018 Sep; 24():6438-6448. PubMed ID: 30213925
[TBL] [Abstract][Full Text] [Related]
33. AEG-1 associates with metastasis in papillary thyroid cancer through upregulation of MMP2/9.
Huang LL; Wang Z; Cao CJ; Ke ZF; Wang F; Wang R; Luo CQ; Lu X; Wang LT
Int J Oncol; 2017 Sep; 51(3):812-822. PubMed ID: 28731152
[TBL] [Abstract][Full Text] [Related]
34. Identification of Differentially Expressed Kinase and Screening Potential Anticancer Drugs in Papillary Thyroid Carcinoma.
Zhang H; Gao B; Shi B
Dis Markers; 2016; 2016():2832980. PubMed ID: 27703281
[No Abstract] [Full Text] [Related]
35. Timosaponin AIII inhibits migration and invasion of A549 human non-small-cell lung cancer cells via attenuations of MMP-2 and MMP-9 by inhibitions of ERK1/2, Src/FAK and β-catenin signaling pathways.
Jung O; Lee J; Lee YJ; Yun JM; Son YJ; Cho JY; Ryou C; Lee SY
Bioorg Med Chem Lett; 2016 Aug; 26(16):3963-7. PubMed ID: 27422337
[TBL] [Abstract][Full Text] [Related]
36. Modifiable risk factors and thyroid cancer.
Stansifer KJ; Guynan JF; Wachal BM; Smith RB
Otolaryngol Head Neck Surg; 2015 Mar; 152(3):432-7. PubMed ID: 25552593
[TBL] [Abstract][Full Text] [Related]
37. Thyroid cancer.
Carling T; Udelsman R
Annu Rev Med; 2014; 65():125-37. PubMed ID: 24274180
[TBL] [Abstract][Full Text] [Related]
38. Molecular pathogenesis and mechanisms of thyroid cancer.
Xing M
Nat Rev Cancer; 2013 Mar; 13(3):184-99. PubMed ID: 23429735
[TBL] [Abstract][Full Text] [Related]
39. TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity.
Freeman GJ; Casasnovas JM; Umetsu DT; DeKruyff RH
Immunol Rev; 2010 May; 235(1):172-89. PubMed ID: 20536563
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer.
Guigon CJ; Fozzatti L; Lu C; Willingham MC; Cheng SY
Carcinogenesis; 2010 Jul; 31(7):1284-91. PubMed ID: 20299527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
